CD274 and cancer: The PD-1/PD-L1 pathway was abnormally activated in various cancers (6, 26), and anti–PD-1/PD-L1 immunotherapy has been widely used or tried in clinical trials in many solid tumors, such as lung cancer, advanced metastatic melanoma, esophagus cancer, and colorectal cancer (27, 28).